Patients' views and experiences of the first community pharmacy-based medication therapy management clinic in the Middle East and North Africa (MENA): A qualitative study. [PDF]
Hadi MA +6 more
europepmc +1 more source
ABSTRACT Traumatic spinal cord injury (TSCI) caused by sharp‐force penetration is exceptionally rare, and the use of high‐dose methylprednisolone (MP) remains highly controversial, especially beyond the conventional 8‐h treatment window. This case report describes a 30‐year‐old male with acute incomplete TSCI following a knife stab wound to the right ...
Honghong Wang +5 more
wiley +1 more source
Racial and ethnic disparities related to the Medicare Part D Medication Therapy Management Program. [PDF]
Allen A, Hung A.
europepmc +1 more source
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi +9 more
wiley +1 more source
Construction on training course and training quality evaluation index system of chronic disease medication therapy management service (MTMs) in China: A Delphi study. [PDF]
Cai W +8 more
europepmc +1 more source
Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni +19 more
wiley +1 more source
The effect of pharmacist-led medication therapy management in the multidisciplinary care of acute kidney injury survivors. [PDF]
Wang T +5 more
europepmc +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
Peng Xie,1,* Hui-Qin Li,1,* Wan-Lin Peng,2 Hao Yang3 1People’s Hospital of Deyang City, Deyang City, Sichuan, 618000, People’s Republic of China; 2School of Nursing, Guangxi University of Chinese Medicine, Nanning, Guangxi, 530004, People’s ...
Yang H, Li HQ, Xie P, Peng WL
core
The effects of medication therapy management on medication utilization among Medicare beneficiaries with HIV/AIDS. [PDF]
Zhang X, Wang J.
europepmc +1 more source

